Matt Turner, President of Patient Affordability at Paysign (PAYS), has introduced ClaimGuardRx, a proprietary large language model built to protect manufacturer affordability program value.
The platform is designed to ensure that every dollar allocated within a pharmaceutical manufacturer’s affordability program is tracked, defended, and optimised effectively.
ClaimGuardRx uses a voice interface to give account teams instant, conversational access to claims intelligence that previously required lengthy manual review processes.
The shift from manual to conversational access represents a significant operational change for teams managing complex pharmaceutical benefit and affordability programs.
Turner has outlined a broad long-term vision for the tool, positioning it as far more than a defensive or monitoring product for existing programs.
According to Turner, ClaimGuardRx “not only defends programs but shapes how they’re designed, priced, and optimized from the start.”
That framing signals an ambition to move the platform upstream into strategic decision-making, rather than deploying it only after programs have already been structured.
Pharmaceutical manufacturers operating affordability programs face mounting pressure to demonstrate that patient support spending delivers measurable outcomes and is not eroded by misuse.
Large language model technology has increasingly been adopted across the healthcare and pharmaceutical sectors to process claims data at a scale and speed that traditional analytics tools cannot match.
Paysign, which trades on the Nasdaq under the ticker PAYS, positions itself as a payments and affordability solutions provider with a specific focus on the pharmaceutical patient support market.
The introduction of ClaimGuardRx reflects a broader industry trend toward embedding artificial intelligence directly into the infrastructure of patient affordability and copay assistance programs.
By shaping program design and pricing from the outset, the platform aims to reduce financial leakage and improve the overall efficiency of manufacturer-funded patient support schemes.